|
Neihu, Taiwan (December 19, 2019)
Abnova announced today it has upgraded its antibody technology and manufacturing for researchers, biotech and pharmaceutical customers worldwide. Abnova’s new antibody production platform DNAx™ Immune uses DNA antigen for direct immunization thereby obviating the traditional peptide and protein antigen for immunization and screening. The technology was developed by an in-house team over three year time span. As such, the generated antibody has an unparallel ability to recognize native protein in its natural state. Starting 2020, Abnova’s DNAx™ Immune will be a catalyst for new antibody products and services to uplift Abnova’s current business in an increasingly competitive bioreagent landscape, and as a turnkey for developing collaborations and partnerships in new emerging markets.
Conventional DNA immunization is hampered by unpredictable antibody response, low antibody titer, and low yield rate for monoclonal antibody. While the technology has been used on-and-off in research, it has not made a significant impact in diagnostics and therapeutics. DNAx™ Immune can be used in all mammalian animals, most commonly mouse, rat, and rabbit for polyclonal and monoclonal antibody production. DNAx™ Immune generated antibody is highly-effective as a staining antibody to identify native protein expression in cell and tissue, as a detecting antibody to quantify and diagnose protein biomarker in blood and urine, and as a targeting antibody to treat diseased protein.
Abnova has identified several new emerging markets to leverage DNAx™ Immune. Exosome for precision medicine diagnosis is coming to maturity. Exosome quantification will require highly-sensitive capturing and detecting antibodies. Ex vivo cell therapy manipulation will require a plethora of high efficiency antibodies for immune cell activation, expansion, and checkpoint blocking, before refusing cells back to the cancer patients. Beyond as platform for antibody production, DNAx™ Immune can be directly utilized a treatment vehicle against infection, cancer, and autoimmune diseases. These emerging fields represent new market opportunities for business and revenue generation for Abnova. |
+886-2-87511888
sales@abnova.com
Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs of the in vitro diagnostic (IVD) industry. Abnova provides its partners and customers access to the technologies, products, and services relating to circulating rare cells, circulating exosomes, and circulating cell-free RNA for early to metastatic to recurrent disease and treatment diagnosis, prediction, guidance, and monitoring. Abnova facility is for proprietary bioreagent and high-throughput automation development and manufacturing for clinical trials and IVD commercialization. (www.abnova.com)